X4 Pharmaceuticals ( (XFOR) ) has released its Q4 earnings. Here is a breakdown of the information X4 Pharmaceuticals presented to its investors.
X4 Pharmaceuticals is a biotechnology company focused on developing treatments for rare immune system diseases, leveraging expertise in CXCR4 biology to address significant unmet medical needs.
The company recently reported its financial results for the fourth quarter and full year of 2024, highlighting the successful U.S. launch of its first product, XOLREMDI® for WHIM syndrome, and ongoing global expansion efforts. X4 also provided updates on its Phase 3 4WARD trial for chronic neutropenia, aiming for full enrollment by late 2025 with top-line data expected in 2026.
Key financial metrics included net revenues of $2.6 million from XOLREMDI sales since its launch in May 2024. The company also reported a strategic restructuring aimed at reducing annual spending by $30-35 million. Despite a net loss of $37.5 million for 2024, X4’s cash position remains strong, bolstered by a $105 million gain from selling a priority review voucher.
Strategically, X4 is expanding its reach through partnerships in Europe, Australia, New Zealand, and the MENA region, while refining its 4WARD trial protocol to focus on patients with the highest unmet needs. The company is optimistic about mavorixafor’s potential to address chronic neutropenia and WHIM syndrome globally.
Looking ahead, X4 Pharmaceuticals is poised to continue its momentum in 2025, with expectations of increased XOLREMDI sales and significant progress in its clinical trials, reflecting management’s confidence in the company’s strategic direction and financial health.